Nordion Inc(USA)  

(Public, NYSE:NDZ)   Watch this stock  
Find more results for NDZ
8.02
+0.90 (12.64%)
May 23 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 7.36 - 8.03
52 week 5.51 - 10.96
Open 7.38
Vol / Avg. 2.09M/156,977.00
Mkt cap 496.51M
P/E     -
Div/yield     -
EPS -0.46
Shares 61.91M
Beta 0.75
Inst. own 85%
Jun 3, 2013
Q2 2013 Nordion Inc. Earnings Release Add to calendar
Mar 6, 2013
Nordion Inc. Annual Shareholder Meeting
Mar 6, 2013
Q1 2013 Nordion Inc. Earnings Conference Call - Webcast
Mar 4, 2013
Q1 2013 Nordion Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Jan '13) 2012
Net profit margin -0.50% -11.79%
Operating margin -10.78% 0.45%
EBITD margin - 12.72%
Return on average assets -0.25% -6.51%
Return on average equity -0.55% -12.04%
Employees 516 -
Carbon Disclosure Rating - -

Address

447 March Rd.
OTTAWA, ON K2K 1X8
Canada
+1-613-5922790 (Phone)
+1-613-5926937 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Nordion Inc. (Nordion)is a global health science company, engaged providing products and services used for the prevention, diagnosis and treatment of disease. The Company�s operations are organized into three business segments: Targeted Therapies, Sterilization Technologies and Medical Isotopes as well as certain corporate functions and activities reported as Corporate and Other. The Company�s Targeted Therapies segment is focused on the targeted treatment of cancer. The Company�s Medical Isotopes segment primarily focuses on products used in the diagnosis and treatment of diseases, including cardiac and neurological conditions, and several types of cancer. The Company�s shared corporate functions and activities are reported as Corporate and Other. The Company has two business units Targeted Therapies and Specialty Isotopes.

Officers and directors

Steven M. West President, Chief Executive Officer, Non-Independent Director
Age: 57
Bio & Compensation  - Reuters
G. Peter Dans Chief Financial Officer
Bio & Compensation  - Reuters
Grant Gardiner Senior Vice President, General Counsel, Corporate Secretary
Bio & Compensation  - Reuters
Christopher Ashwood Senior Vice President - Corporate Services
Bio & Compensation  - Reuters
Jill Chitra Senior Vice President - Quality and Regulatory Affairs
Bio & Compensation  - Reuters
Tamra Benjamin Vice President - Public Affairs
Bio & Compensation  - Reuters
Tom Burnett General Manager - Medical Isotopes
Bio & Compensation  - Reuters
Scott McIntosh Chief Operating Officer - Specialty Isotopes
Bio & Compensation  - Reuters
William D Anderson Non-Executive Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Jeffrey J. Brown Independent Director
Age: 51
Bio & Compensation  - Reuters